<DOC>
	<DOCNO>NCT02916160</DOCNO>
	<brief_summary>Chronic Heart Failure ( CHF ) frequent pathology burden mortality significant morbidity . Sleep apnea syndrome ( SAS ) frequently associate CHF 20 % 75 % case . Treatment SAS however inconsistently associate decline morbidity mortality . To date , CHF medical treatment report inconsistently efficient treatment SAS . SACUBITRIL-VALSARTAN ( ENTRESTO® ) new treatment CHF recently indicate class I , level B recent European Society Cardiology ( ESC ) guideline 2016 CHF . PARADIGM-HF trial demonstrate morbidity mortality improve SACUBITRIL-VALSARTAN . In comparison enalapril , reduce occurrence cardiovascular death hospitalisation CHF 20 % 16 % reduction all-cause mortality . The purpose research evaluation SACUBITRIL-VALSARTAN combination CHF patient present sleep apnea syndrome . A three month real life observational trial perform . A measure Apnea Hypopnea Index realise 3 month SACUBITRIL-VALSARTAN treatment . A concomitant evaluation cardiological quality life parameter realize .</brief_summary>
	<brief_title>Sacubitril-valsartan Heart Failure Patients : ENTRESTO-SAS Study</brief_title>
	<detailed_description>The Chronic Heart Failure ( CHF ) frequent pathology burden mortality significant morbidity . Chronic HF provide almost 2 % health expenditure develop country , large expenditure item USA ( 34.8 billion dollar ) . In developed country , include France , mortality 1 year diagnosis chronic HF 40 % , 50 % 2 year , 70 % 4.5 year . Sleep apnea syndrome ( SAS ) frequently associate HF 20 % 75 % case . The presence apnea syndrome associate great morbidity mortality . Treatment SAS however inconsistently associate decline morbidity mortality . To date , CHF medical treatment report inconsistently efficient treatment SAS : 6 study correspond total 67 patient 5 type molecule report incomplete effect central component Apnea Hypopnea Index ( AHI ) patient . SACUBITRIL - VALSARTAN ( ENTRESTO® ) new treatment HF recently indicate class I , level B recent ESC guideline 2016 HF . It combine inhibitory prodrug neprilysin valsartan . After initial failure neprilysin inhibition alone dual neprilysin-angiotensin convert enzyme ( ACE ) inhibition , PARADIGM-HF trial demonstrate morbidity mortality improve SACUBITRIL - VALSARTAN combination ( formerly LCZ696 ) . In comparison ACE inhibitor enalapril , sacubitril/valsartan reduce occurrence primary end point ( cardiovascular death hospitalisation HF ) 20 % 16 % reduction all-cause mortality . These finding suggest sacubitril/valsartan replace ACE inhibitor angiotensin receptor blocker foundation treatment symptomatic patient ( NYHA II-IV ) HF reduce ejection fraction . The purpose research evaluation SACUBITRIL-VALSARTAN CHF patient present sleep apnea syndrome . We speculate synchronously beneficial effect heart failure , SACUBITRIL-VALSARTAN combination could improve associate SAS particular central component AHI index . After exhaustive initial pre-therapeutic evaluation , SACUBITRIL-VALSARTAN combination treatment initiate 3 month . The pre-therapeutic evaluation include cardiological biological exam , quality life questionaries nocturnal ventilatory polygraphy . Considering result polygraphy , three group patient identify : - group 1 patient , characterized central AHI ≥5 / h obstructive AHI &lt; 15 / h , - group 2 patient , characterize obstructive AHI ≥15 / h whatever central component . In group patient , ventilator treatment constant positive airway pressure auto-servoventilation start . - group 3 patient , characterized central AHI &lt; 5 / h obstructive AHI &lt; 15 / h. After three month treatment , final evaluation include cardiological biological exam , quality life questionaries patient include trial . A nocturnal polygraphy perform group 1 2 patient . For group 2 patient treated device , observance device , residual AHI device pressure device measure .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Age great equal 18 year Patient chronic heart failure ( LVEF ≤ 45 % ) . Written inform consent Renal insufficiency ( GF &lt; 30 milliliters/min ) Pregnancy Allergy one compound Personal history angiooedema Hemodynamical instability Severe hepatopathy Current treat hyperkaliemia Prognosis &lt; 6months Current CPAP ASV treatment Sleep Apnea Syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Heart failure</keyword>
	<keyword>Sleep Apnea Syndrome</keyword>
	<keyword>Continuous Positive Airways Pressure</keyword>
	<keyword>SACUBITRIL - VALSARTAN</keyword>
</DOC>